Bionano Genomics (BNGO) Depreciation & Amortization (CF) (2017 - 2026)

Bionano Genomics (BNGO) has 10 years of Depreciation & Amortization (CF) data on file, last reported at $2.3 million in Q1 2026.

• For the quarter ending Q1 2026, Depreciation & Amortization (CF) fell 5.09% year-over-year to $2.3 million; the trailing twelve-month figure through Mar 2026 stood at $8.2 million (down 12.62% YoY), and the FY2025 full-year result was $9.5 million, down 32.06% from the prior year.
• Depreciation & Amortization (CF) retreated to $2.3 million in Q1 2026, from $2.3 million in the prior quarter.
• In the past five years, Depreciation & Amortization (CF) ranged from a high of $3.6 million in Q3 2023 to a low of $1.8 million in Q3 2025.
• A 5-year average of $2.6 million and a median of $2.4 million in 2022 frame the typical range for Depreciation & Amortization (CF).
• Across the five-year window, Depreciation & Amortization (CF) surged 393.3% in 2022 and slumped 36.74% in 2024, its largest moves.
• Tracing BNGO's Depreciation & Amortization (CF) over 5 years: stood at $2.8 million in 2022, then jumped by 30.01% to $3.6 million in 2023, then slumped by 33.31% to $2.4 million in 2024, then slipped by 2.54% to $2.3 million in 2025, then slipped by 1.16% to $2.3 million in 2026.
• Business Quant data shows BNGO's Depreciation & Amortization (CF) at $2.3 million in Q1 2026, $2.3 million in Q4 2025, and $1.8 million in Q3 2025.